Ms Susan Galbraith, head, oncology innovative medicines unit, AstraZeneca
The research will complement AstraZeneca's strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.
The research collaboration will involve Redx Pharma scientists working with AstraZeneca's oncology innovative medicines group to accelerate the drug discovery process.
Redx Pharma will use its early stage drug discovery capabilities to identify novel leads whose further development will be supported by AstraZeneca's extensive knowledge of the area and strong oncology expertise.
Under the terms of the agreement, Redx Pharma will receive an undisclosed upfront payment.
In addition, Redx Pharma is potentially eligible for significant development and commercial milestones, as well as tiered royalties as the program progresses.